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Abstract
Background: This study is a retrospective evaluation of the efficacy of neoadjuvant chemotherapy
(NC) with a vinorelbine (V) and epirubicin (E) intravenous combination regimen and is aimed at
identification of predictive markers for the long-term outcome in noninflammatory locally advanced
breast cancer (NLABC).
Methods: One-hundred-and-nineteen patients with NLABC were identified from September 2001
to May 2006. Analysis was performed in March 2008, with a median follow-up of 63.4 months
(range, 9-76 months). All patients were diagnosed with invasive breast cancer using 14 G core
needle biopsy and treated with three cycles of VE before surgery. Local-regional radiotherapy was
offered to all patients after the completion of chemotherapy followed by hormonal therapy
according to hormone receptor status. Tissue sections cut from formalin-fixed paraffin-embedded
blocks from biopsy specimens and postoperative tumor tissues were stained for the presence of
estrogen receptor (ER), progesterone receptor (PgR), HER-2 (human epidermal growth factor
receptor-2), and MIB-1(Ki-67).
Results: Patients characteristics were median age 52 years (range: 25-70 years); clinical TNM
stage, stage IIB (n = 32), stage IIIA (n = 56), stage IIIB (n = 22) and stage IIIC (n = 9). All patients
were evaluable for response: clinically complete response was documented in 27 patients (22.7%);
78 (65.6%) obtained partial response; stable disease was observed in 13 (10.9%); 1 patient (0.8%)
had progressive disease. Pathological complete response was found in 22 cases (18.5%). Seventy-
five patients were alive with no recurrence after a median follow-up of 63.4 months, the 5-year
rates for disease-free survival and overall survival were 58.7% and 71.3%, respectively, after the
start of NC. On multivariate analysis, the independent variables associated with increased risk of
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relapse and death were high pre-Ki-67(p = 0.012, p = 0.017, respectively), high post-Ki-67
expression (p = 0.045, p = 0.001, respectively), and non-pCR (p = 0.034, p = 0.027, respectively).
A significantly increased risk of death was associated with lack of pre-ER expression (p = 0.002).
Among patients with non-pCR, those with a pathological response at the tumor site with special
involvement (i.e. skin, vessel and more than one quadrant) were at a higher risk of disease relapse
and death (p < 0.001, p = 0.001, respectively).
Conclusion: This study suggests the promising use of a VE regimen as NC for Chinese NLABC
after a median follow-up of 63.4 months. Pathological response in the tumor site, pre-Ki-67 and
post-Ki-67 expression, and pre-ER expression were the important variables that predicted long-
term outcome. Patients with pathological special involvement at the primary site after NC had the
lowest survival rates.
Background
Locally advanced breast cancer (LABC) comprises a heter-
ogeneous group of breast neoplasms, from stages IIB to
IIIC according to the American Joint Committee on Can-
cer (AJCC) staging system [1]. These cancers are distinct
from other breast cancers in terms biological characteris-
tics and clinical behavior, showing aggressive behavior
and highly angiogenic characteristics. Neoadjuvant chem-
otherapy (NC) or primary chemotherapy is at present the
standard therapy for LABC, and an increasingly popular
treatment strategy for operable breast cancers [2-7]. NC
allows regression of the tumor in order to avoid mastec-
tomy and to eliminate clinically undetectable microme-
tastases. In addition, NC permits the assessment of the
response of the primary tumor to a particular chemother-
apy regimen and provides an early opportunity to change
therapeutic agents if the tumor appears clinically resistant.
A series of anthracyclines and vinorelbine combination in
advanced or metastatic breast cancer was reported during
the 1990s [8-12]. Only one phase III randomized trial of
MA8, conducted by the National Cancer Institute of Can-
ada (NCIC) in 2000, compared single-agent doxorubicin
with the combination of vinorelbine plus doxorubicin in
metastatic breast cancer, and failed to show any added
effect for the combination[9]. However, before 2001,
there were no published clinical trials of epirubicin-vinor-
elbine based combinations for neoadjuvant treatment in
LABC. We conducted a phase II prospective clinical trial of
vinorelbine and epirubicin (VE) as a NC regimen in the
treatment of Chinese LABC at the Cancer Hospital of
Fudan University from September 2001 to December
2004; this study was approved by the institutional review
board of my institution [13]. Based on the positive results
of this regimen and the absence of a standard chemother-
apy regimen for LABC in China at the time, some patients
with LABC continued the treatment after the completion
of the study. These patients were informed of the risks and
benefits of the treatment, and provided written informed
consent. Since the prognoses of noninflammatory locally
advanced breast cancer (NLABC) and inflammatory
breast cancer (IBC) are different, despite similar treatment
regimens[14], we retrospectively analyzed the data of
NLABC patients who received VE as a neoadjuvant chem-
otherapy regimen from September 2001 to May 2006 at
our institution. We evaluated the efficacy of VE and the
impact of clinical, pathological, and immunohistochemi-
cal features of breast cancer on survival after a median fol-
low-up of 63.4 months in order to identify biomarkers
that may effectively predict the long-term outcome of this
combination regimen in NLABC.
Methods
Patient Selection
From September 2001 to May 2006, 119 patients with
NLABC who had been treated with three cycles of NC with
intravenous VE regimen and without other local or sys-
temic treatment before surgery were identified at the Can-
cer Hospital of Fudan University in China. The VE
regimen consisted of 25 mg/m2 of intravenous V given on
day 1 and on day 8 plus 60 mg/m2 of E given on day 1 and
then every 21 days. Other eligibility criteria for the this
study met by all patients were being female, 18-70 years
of age, no other malignant tumors or tumor history, diag-
nosis with invasive breast cancer via 14 G core needle
biopsy, lack of metastatic spread as excluded by chest X-
ray and abdominal ultrasound before or after initial diag-
nosis, and adequate cardiac, renal and hepatic function as
well as normal marrow reserves. The baseline work-up
before neoadjuvant chemotherapy included a complete
history and clinical examination, bilateral mammogra-
phy, bilateral breast and axillary ultrasound, and percuta-
neous cytology of lymph nodes by fine-needle aspiration
(FNA) to assess potential clinically suspicious lymph
node involvement.
All patients gave written informed consent and the study
protocol was designed according to the principles of the
Helsinki guidelines and approved by the institutional
review board of my institution.BMC Cancer 2009, 9:375 http://www.biomedcentral.com/1471-2407/9/375
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Toxicity was assessed through clinical or laboratory exam-
ination, or through other special examinations such as
EKG if considered necessary before each cycle of chemo-
therapy and surgery. A complete blood cell count was
repeatedly performed every 2-4 days during chemother-
apy in order to detect hematologic side effects. World
Health Organization (WHO) criteria were applied to eval-
uate the toxicities of the neoadjuvant chemotherapy
Treatment
After full assessment of response and restaging within 2
weeks from the last NC session, all patients were subjected
to surgery within 4 weeks. Because the breast-conserving
therapy is not widely accepted by Chinese patients,
accounting for less than 10% of operable breast cancers as
reported by Zhang[15], all patients in our study chose
modified radical mastectomy or radical mastectomy if the
residual tumor invaded the pectoralis major muscle. Sub-
sequently, patients received three cycles of VE as adjuvant
chemotherapy after surgery, if clinical complete response
(cCR) or clinical partial responses (cPR) were achieved.
The FEC regimen, consisting of 500 mg/m2 of intrave-
nous 5-fluorouracil, 75 mg/m2 of epirubicin and 600 mg/
m2 of cyclophosphamide given on day1 and then every 3
weeks for 3 cycles was administered in patients with clin-
ically stable disease (cSD) and clinically progressive dis-
ease (cPD). All patients received a total of six
chemotherapy cycles.
Local-regional radiotherapy was offered to all patients
within 4 weeks after the completion of adjuvant chemo-
therapy and was given over 5 weeks with a total dose of
50-60 Gy in 1.8-2.0 Gy daily fractions to the breast, inter-
nal mammary lymph nodes, and supraclavicular axillary
lymph node areas. Hormonal adjuvant therapy was
offered to all ER or PR positive patients before exposure to
NC or after surgery; this consisted of tamoxifen for pre-
menopausal patients and aromatase inhibitors for post-
menopausal patients. Hormonal adjuvant therapy was
started at the end of adjuvant treatment.
Assessment of Response
Clinical, mammographic, and ultrasound measurements
were recorded before treatment and at the end of the cyto-
toxic treatment before surgery. The clinical assessment of
response was based on measurements of the longest
diameter of the tumor and node according to the standard
of RECIST (response evaluation criteria in sold
tumors)[16], and was classified as follows: clinical com-
plete response (cCR), the disappearance of disease; clini-
cal partial response (cPR), at least a 30% decrease; clinical
progressive disease (cPD), at least a 20% increase in the
sum of the longest diameter of target lesions or the
appearance of new lesions; clinical stable disease (cSD),
neither sufficient shrinkage to qualify for cPR nor suffi-
cient increase to qualify for cPD.
The pathological response was evaluated after surgical
resection of the remaining tumor. Pathologic response in
the primary site (pRT) was classified as follows: T-A) no
tumor cell or presence of in situ carcinoma, no invasive
tumor; T-B) presence of invasive carcinoma without spe-
cial involvement (i.e., skin, vessel, more than one quad-
rant); T-C) presence of invasive carcinoma with special
involvement(i.e., skin, vessel, more than one quadrant). A
pathological response was considered complete (pCR) if
no residual or in situ tumor could be detected (pCR = T-A,
non-pCR = T-B+ T-C).
Immunohistochemistry and Scoring methods
Tissue sections were cut from formalin-fixed paraffin-
embedded blocks prepared from biopsy specimens and
postoperative tumor tissue. Sections containing represent-
ative tumor samples were assayed by immunohistochem-
istry for the presence of the estrogen receptor (ER),
progesterone receptor (PgR), HER-2 (human epidermal
growth factor receptor-2), and MIB-1(Ki-67). Immuno-
histochemistry and the scoring of immunohistochemical
staining of ER, PR and Her-2/neu were carried out in the
pathology department of our hospital. Staining results
were assessed by at least two pathologists using a semi-
quantitative scoring system, and the final score was calcu-
lated as the product of a proportion score and an intensity
score. The proportion score, indicating the percentage of
tumor cells stained, was interpreted as follows: a score of
0 represented no staining seen, one represented ≤ 25% of
cells positive, two represented 25-50% of cells stained,
three represented 50-75% of positive cells and four repre-
sented >75% of cells showing positive staining. According
to the intensity score, a negative result was defined as a
score of 0, weakly positive as one, moderately positive as
two, and strongly positive as three. The staining results
therefore ranged from score 0 to 12. The scoring system
for ER and PR was defined as negative for a score of 0 and
positive for scores of 1 through 12 based on the nucleic
staining of carcinoma cells. Her-2/neu staining was
defined as negative for scores of 0-8 (namely, 0, 1+ and 2+
in the DAKO scoring system) and positive for a strong
membranous staining with scores of 9-12 (namely DAKO
score 3+). The Ki-67 score was counted in a minimum of
10 randomly selected 40× high-power fields containing
representative sections of tumor tissue and calculated as
the percentage of positively stained cells as compared to
total cells.
Statistical Analysis
Statistical analyses were performed using SPSS statistical
software package 15.0. Relationships between dichoto-
mous variables were analyzed using a chi-square test or
Fisher's exact test, where appropriate. P-values < 0.05 were
considered significant. Ki-67 as a continuous variables
was defined as high expression (>20%) or low expression
(≤ 20%) according to their median expression level beforeBMC Cancer 2009, 9:375 http://www.biomedcentral.com/1471-2407/9/375
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NC. Results were last updated in March 2008. A total of
109 patients were evaluated with the paired correlation
before and after surgery, the other 10 patients showed no
residual tumor in the postoperative tissue. Disease-free
survival (DFS) was defined as the time elapsed between
the date of the start of NC and the date of first time
relapse, wherever this relapse might be. Death in patients
without a record of relapse was counted as an event for
disease-free survival. Overall survival (OS) was the time
between the date of initial diagnosis and date of last status
report, with the patient being alive or dead and regardless
of the cause of death. Survival analyses were performed
using the Kaplan and Meier method, and the differences
between groups with regard to survival time were evalu-
ated by the log-rank test. Univariate analyses (log-rank
tests) and multivariate analyses (Cox regression analyses)
were performed to identify risk factors associated with
DFS and OS.
Results
Patient characteristics before and after chemotherapy
From September 2001 to May 2006, one hundred and
nineteen patients with NLABC were identified. The
median age at diagnosis was 52 years (range, 25 -70 years)
and 50 (42%) of these women were younger than 50
years. Only one patient with disease progression after two
cycles of primary VE combination was submitted to local
treatment. The distribution of clinical involvement
showed that all the patients had tumors >2.0 cm. The
characteristics of all patients before and after surgery were
summarized in Table 1.
Clinical Response and Pathological Evaluation
As shown in Table 1, clinical evaluation of the treatment
efficacy indicated overall responses in 105 of the 119
patients (88.3%), with 27 (22.7%) cCR, and 78 (65.6%)
cPR.
Table 1: Patient Characteristics before and after Surgery (n = 119)
Characteristics No.(%) Characteristics No.(%)
Clinical stage Grade
II B 32 (26.9%) I 1 (0.8%)
III A 56 (47.1%) II 67 (56.3%)
III B 22 (18.5%) III 15 (12.6%)
III C 9 (7.5%) Not graded 36 (30.3%)
Pre-cALN Post-cALN
negative 36 (30.3%) negative 81 (68.1%)
positive 83 (69.7%) positive 38 (31.9%)
Pre-ER Post-ER
negative 58 (48.7%) negative 82 (75.2%)
positive 61 (51.3%) positive 27 (24.8%)
Pre-PR Post-PR
negative 60 (50.4%) negative 84 (77.1%)
positive 59 (49.6%) positive 25 (22.9%)
Pre-HER-2 Post-HER-2
0-2+ 86 (72.3%) 0-2+ 79 (72.5%)
3+ 33 (27.7%) 3+ 30 (27.5%)
Pre-Ki67 Post-Ki67
≤ 20% 74 (62.2%) ≤ 20% 93 (85.3%)
>20% 45 (37.8%) >20% 16 (14.7%)
Pathology Pathological tumor size
IDC 92 (77.3%) ≤ 2 cm 28 (23.5%)
ILC 4 (3.4%) > 2 cm 59 (49.6%)
other 23 (19.3%) unmeasured 32 (26.9%)
Clinical response pALN
CR 27 (22.7%) N 0 39 (32.8%)
PR 78 (65.6%) N 1-3 24 (20.2%)
SD 13 (10.9%) N 4-9 35 (29.4%)
PD 1 (0.8%) N >9 21 (17.6%)
Pathological response in tumor site
T-A 22 (18.5%)
T-B 75 (63.0%)
T-C 22 (18.5%)
Abbreviations: pre-, before chemotherapy; post-, after chemotherapy; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; 
IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; 
T-A: no tumor cell or presence of in situ carcinoma, no invasive tumor; T-B: presence of invasive carcinoma without special involvement (such as 
skin, vessel, more than one quadrant); T-C: presence of invasive carcinoma with special involvement.
109 patients were evaluated after neoadjuvant chemotherapy, because of 10 patients with no residual tumor in postoperative tissue.BMC Cancer 2009, 9:375 http://www.biomedcentral.com/1471-2407/9/375
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A total of 117 patients underwent modified radical mas-
tectomy, and 2 patients had radical mastectomy. All
patients received examination of over 10 axillary lymph
nodes. The pCR in the breast was achieved in 22 patients
(18.5%) and in the axillary lymph nodes in 39 patients
(32.8%), while absence of tumors in the breast occurred
in 10 patients (8.4%). For patients who experienced a
pCR, 68.2% of the tumors were pre-ER negative and
31.8% pre-ER positive. Pre-ER negative patients were
more likely to achieve pCR after NC (p = 0.043, Table 2).
At surgery, the median number of involved nodes was 4
(range, 0-28). Among 80 patients who showed patholog-
ical evidence of node involvement after surgery, 24
(20.2%) were N1-3, 35 (29.4%) were N4-9, and 21
(17.6%) were N>9. 83 of 119 patients had percutaneous
cytological evidence of node involvement before neoadju-
vant chemotherapy. Among these patients, pathological
nodes were found in 59 of 83 patients (71.1%). Patholog-
ical nodes were found in 21 of 36 patients (58.3%) with-
out clinical node involvement or for whom percutaneous
cytology was negative disease before neoadjuvant chemo-
therapy.
Biomarker expression
The evaluation of ER, PR, Ki-67, and HER-2 protein
expression was possible in 119 patients before NC and in
109 patients after NC, because the postoperative tissue
did not contain tumor cells for analysis in 10 patients.
Positive ER expression was detected in 61 of 119 patients
(51.3%) before and in 27 of 109 patients (24.8%) before
and after surgery, respectively. The expression of PR pro-
tein was positive in 59 patients (49.6%) and 25 patients
(22.9%) before and after surgery, respectively. High HER-
2 protein expression was observed in 33 patients (27.7%)
before NC. After NC, high expression of HER-2 protein
was observed in 30 patients (27.5%). The median and
range of Ki-67 indices before NC and after surgery were
21.9% (0%-67%), and 11% (0%-62%), respectively. We
recorded the Ki-67 as high expression (>20%) and low
expression (≤ 20%). High Ki-67 protein expression was
observed in 45 patients (37.8%) before NC. After NC,
high expression of Ki-67 protein was observed in 16
patients (14.7%). Table 1 shows immunohistochemical
protein expression levels (ER, PR, HER-2, and Ki-67)
before (pre-)and after (post-)surgery.
Toxicity of the regimens
The combination of vinorelbine and epirubicin was well
tolerated with no case of death due to drug-related toxic-
ity. The toxicities associated with therapy are summarized
in Table 3. Neutropenia was the major hematologic toxic-
ity. Grade 3-4 neutropenia was observed in 55 patients
(46.2%) and 27.3% of chemotherapy induction cycles.
Febrile neutropenia was found in 16 patients (13.4%) but
only 5 patients (4.2%) required hospitalization. Signifi-
cant anemia and thrombocytopenia associated with ther-
apy were very scarce. The most common nonhematologic
toxicity was alopecia and nausea/vomiting. Grade 3 alo-
pecia was seen in 63.6% of patients. Almost all patients
experienced different degrees of nausea/vomiting after the
administration of chemotherapy and grade 3 nausea/
vomiting was found in 12.6% patients. Five patients expe-
rienced grade 3 mucositis. The other nonhematologic tox-
icities were minimal and clinically insignificant.
Follow-up and Survival
The study was analyzed in March 2008, with a median fol-
low-up of 63.4 months (range, 9-76 months). 115
patients were evaluable for survival (4 patients were lost
to follow-up). After the median follow-up, the 5-year rates
for DFS and OS were 58.7% and 71.3%, while 6-year rates
for DFS and OS were 55.0% and 68.2%, respectively, after
the start of chemotherapy. Of the 43 patients who had
relapsed, 2 had local recurrence, 6 had local and meta-
static recurrence, and 35 had contralateral or metastatic
recurrence. Of the 28 patients who died, 22 died as a result
of liver or lung failure due to metastasis.
We evaluated the impact of clinical (age, clinical stage
before NC, clinical ALNs status before and after surgery,
clinical response), pathological (histological grade, tumor
size, pathology, axillary lymph node status, and patholog-
ical response) and immunohistochemical (ER, PR, Ki-67
and HER-2 protein expression before and after surgery)
features on disease free survival (DFS) and overall survival
(OS).
Table 2: Relations between pre-ER and Pathological Response in Tumor Site
Pathological Response in Tumor Site pre-ER p value
negative positive total
pCR 15(68.2%) 7(31.8%) 22(100%) 0.043
non-pCR 43(44.3%) 54(55.7%) 97(100%)
total 58 61 119
Abbreviations: pCR: pathological complete response; pre-ER:ER status examined before neoadjuvant chemotherapy.BMC Cancer 2009, 9:375 http://www.biomedcentral.com/1471-2407/9/375
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As table 4 shows, univariate analysis of pCR (p < 0.001, p
= 0.003, respectively) and low post-Ki-67expression (p =
0.025, p = 0.001, respectively) revealed association with
significantly decreased risk of relapse and death. A signif-
icantly increased risk of death was associated with lack of
pre-ER or pre-PR expression (p = 0.045, p = 0.026, respec-
tively). There was no relationship between clinical
response (p = 0.284, p = 0.651, respectively) and patho-
logical axillary lymph node status (p = 0.456, p = 0.425,
respectively) with DFS and OS.
On multivariate analysis, high pre-Ki-67 (p = 0.012, p =
0.017, respectively) and post-Ki-67 expression (p = 0.045,
p = 0.001, respectively), and non-pCR (p = 0.034, p =
0.027, respectively) were independent variables associ-
ated with the increased risk of relapse and death (Table 5).
Compared to other pathological responses in the tumor
site, patients with special involvement had the worst sur-
vival rates, indicating that more effective adjuvant chemo-
therapy may be considered for treatment of these patients.
Figures 1 and 2 showed the Kaplan-Meier curve for DFS
and OS according to the pathological response in the
tumor site.
Discussion
LABC remains a major clinical problem despite significant
progress made in the treatment. Despite of a multi-disci-
plinary approach including surgery, chemotherapy, endo-
crine therapy and radiation therapy, most patients with
LABC have a poor prognosis. NC is now the standard ther-
apy for LABC and an increasingly popular treatment strat-
egy for operable breast cancer. Several landmark clinical
trials have shown that NC is at least as effective as post-
operative adjuvant chemotherapy with the same regimen
in terms of disease-free and overall survival in operable
breast cancer [17-19].
In order to find predictors for survival after NC in primary
tumors, we assessed clinical and tumor biologic parame-
ters that were measured before and after NC in 119
NLABC patients treated with VE. Although breast conser-
vation surgery after NC was offered and its advantages
were explained by surgeons, all patients with LABC in our
study chose modified radical mastectomy or radical mas-
tectomy if the residual tumor invaded the pectoralis major
muscle. IBC and LABC are both locally advanced breast
carcinomas with poor prognosis, and are often grouped
together in clinical trials. However, IBC and LABC are dis-
tinct clinicopathologic entities with different prognostic
factor profiles including age-specific incidence rate pat-
terns, presence of key pathways and protein expres-
sion[14]. To avoid potential confounding factors, IBC was
excluded from our study.
In our study, the clinical overall response rate (cCR+cPR)
was 88.3%, with pCR in 18.5% of patients. With a median
follow-up of 63.4 months, the 5-year rate for DFS and OS
was 58.7% and 71.3%. The results are consistent with
other reports for the vinorelbine-containing neoadjuvant
chemotherapy, where the clinical response rate varies
from 42% to 98%, and the pCR ranges from 4.2% to 32%
[20-25]. In comparison to the results of NSABP B-27 as
reported by Bear et al. [26], the VE regimen in our study
reached a higher pCR rate than the AC regimen (12.6%),
and a lower rate than AC following docetaxel treat-
ment(26.1%). The 5-year DFS and OS were inferior to AC
or AC following docetaxel arm in the Bear study. These
differences in results could be due to the fact that all
patients had LABC in our study, while only patients with
primary breast tumors larger than 1 cm in diameter were
included in the study by Bear[27].
It is generally held that the tumor response to neoadju-
vant chemotherapy should be strongly correlated with the
long-term outcome of patients. Fisher et al. [17] reported
that women whose tumors were no longer clinically evi-
dent after NC had a better outcome than those whose
tumors showed a cPR to therapy. The latter fared only
marginally better than women whose tumors had a cSD
and cPD, even though all tumors designated as cPR
decreased in size by more than 50% in their study. How-
ever, in the multivariate analysis of our study, the clinical
response was not predictive of DFS or OS. We assume that
the shrinkage of primary tumors after NC may not com-
pletely represent the intrinsic nature of the malignant
tumors. As reported in the literature [26,28-30], tumors
with relatively poor prognostic factors are more sensitive
to NC and more likely to achieve pCR. This type of tumor
tends to respond initially to chemotherapy but then
relapsed rapidly, while relatively low-risk tumors do not
show a marked response but progress rather slowly. In
addition, the patients included in this study had advanced
disease(IIBIIIC), which may also account for the lack of
difference in survival based on response to therapy. Clin-
ical tumor response was assessed by palpation, which is a
rather crude and subjective measure for tumor regression.
Table 3: Grade 3-4 toxicity
Toxicity No. %
Neutropenia 55 46.2%
Anemia --- ---
Thrombocytopenia 2 1.7%
Alopecia 76 63.9%
Nausea/vomiting 15 12.6%
Mucositis 5 4.2%
Hepatic function 3 2.5%
Neuropathy --- ---
Cardiac function --- ---BMC Cancer 2009, 9:375 http://www.biomedcentral.com/1471-2407/9/375
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Table 4: Relations between pre-ER and Pathological Response in Tumor Site
DFS OS
Variables No.(%) Log-Rank P No.(%) Log-Rank P
Before surgery
Age
≤ 50 30(41.7%) 36(41.4%)
>50 42(58.3%) 0.792 51(58.6%) 0.638
Clinial stage
II B 20(27.8%) 23(26.4%)
III A 34(47.2%) 39(44.9%)
III B 14(19.4%) 18(20.7%)
III C 4(5.6%) 0.517 7(8.0%) 0.195
cALN
negative 21(29.2%) 25(28.7%)
positive 51(70.8%) 0.522 62(71.3%) 0.295
ER
negative 33(45.8%) 37(42.5%)
positive 39(54.2%) 0.580 50(57.5%) 0.045
PR
negative 32(44.4%) 38(43.7%)
positive 40(55.6%) 0.155 49(56.3%) 0.026
HER-2
0-2+ 52(72.2%) 63(72.4%)
3+ 20(27.8%) 0.778 24(27.6%) 0.643
Ki67
≤ 20% 49(68.1%) 58(66.7%)
>20% 23(31.9%) 0.071 29(34.3%) 0.055
Pathology
IDC 57(79.1%) 69(79.3%)
ILC 2(2.8%) 2(2.3%)
other 13(18.1%) 0.987 16(18.4%) 0.934
Clinical response
CR 20(27.8%) 11((12.6%)
PR 44(61.1%) 54(62.2%)
SD 7(9.7%) 21(24.1%)
PD 1(1.4%) 0.284 1(1.1%) 0.651
After surgery
cALN
negative 49(68.1%) 60(69.0%)
positive 23(31.9%) 0.848 27(31.0%) 0.912
ER
negative 55(76.4%) 67(77.0%)
positive 17(23.6%) 0.965 20(23.0%) 0.827
PR
negative 54(75.0%) 67(77.0%)
positive 18(25.0%) 0.428 20(23.0%) 0.864
HER-2
0-2+ 50(69.4%) 60(69.0%)
3+ 22(30.6%) 0.568 27(31.0%) 0.328
Ki67
≤ 20% 66(91.7%) 80(92.0%)
>20% 6(8.3%) 0.025 7(8.0%) 0.001
pALN
N 0 23(31.9%) 27(31.0%)
N 1-3 18(25.0%) 20(23.0%)
N 4-9 18(25.0%) 23(26.5%)
N >9 13(18.1%) 0.456 17(19.5%) 0.425
Pathological tumor size
≤ 2 cm 14(19.4%) 18(20.7%)BMC Cancer 2009, 9:375 http://www.biomedcentral.com/1471-2407/9/375
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The pathological response to NC, as determined by an
individual in vivo chemo-sensitivity test, reflects tumor
biology more accurately and might be a better predictor of
outcome. Pathological complete response (pCR) has been
confirmed to be associated with prolonged disease-free
and overall survival [31,32], and thus has been used as the
primary endpoint instead of OS in clinical trials. In our
study, all patients achieving pCR were alive after a median
follow-up of 63.4 months, except for one patient who had
local recurrence. Compared to non-pCR patients, those
with pCR had significantly lower risk of recurrence or
death on univariate and multivariate analysis. As other
studies have reported[26,28-30], we found that those
patients who were ER negative patients before treatment
were more likely to achieve pCR than ER positive patients.
The pCR as a pure surrogate end point still has its limita-
tions. In the latest report of a 16-year follow-up of the
NSABP B27 study[26], the addition of neoadjuvant
docetaxel to the AC regimen resulted in a doubled pCR
rate but not in an increased survival rate, suggesting that
pCR of the breast may not completely take the place of OS
as the surrogate end point for neoadjuvant chemotherapy
studies. Generally, a large number of patients do not
achieve pCR of the breast after NC. This group of patients
also has divergent outcomes due to the histological heter-
ogeneity of their breast cancer and is not deemed to have
a worse outcome. It is therefore of great importance to
identify other predictors of long-term outcome in addi-
tion to pCR of the breast.
ALN status has emerged as an important predictor of long-
term survival in adjuvant chemotherapy. We expected
ALN status before NC and pathologic axillary node
involvement to be related to survival. However, we did
not find a significant correlation between lymph node sta-
tus and patients outcome. The prognostic impact of ALNs
might be substantially diminished after NC for LABC
patients. This result is inconsistent with the finding of
Hennessy et al. [32]. These discordant results may be
partly explained by the differences in drugs and dosages
received by the different patients in each study. Moreover,
we failed to find any relationship between pathologic axil-
lary node status and pathological response of the tumors
after NC. The biological behaviors of tumor cells appeared
to be quite different between primary site and remote
sites. However, we cannot exclude the possibility that the
limited number of samples included in the analysis may
have influenced the results.
The present study investigated the potential relationships
between several biomarkers (ER, PR, HER-2 and Ki-67)
and the long-term outcome of patients. Hormone recep-
tor status has proven to be among the most important pre-
dictive markers for selection of systemic therapy, but its
prognostic value, is less clear. In our study, ER and PR sta-
tus before chemotherapy could prognosticate the OS by
> 2 cm 41(56.9%) 48(55.2%)
unmeasured 17(23.7%) 0.256 21(24.1%) 0.303
Grade
I 1(1.4%) 1(1.2%)
II 39(54.2%) 47(54.0%)
III 8(11.1%) 11(12.6%)
Not graded 24(33.3%) 0.624 28(32.2%) 0.827
pathological response in tumor site
pCR 21(29.2%) 22(25.3%)
non-pCR 51(70.8%) <0.001 65(74.7%) 0.003
Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; 
pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, 
stable disease; PD, progressive disease; pCR, pathological complete response.
109 patients were evaluated after neoadjuvant chemotherapy, because of 10 patients with no residual tumor in postoperative tissue.
*115 Patients were evaluable for survival (4 patients were lost to follow-up)
Table 4: Relations between pre-ER and Pathological Response in Tumor Site (Continued)
Table 5: Multivariate analyses of characteristics before and after surgery in 115 patients as predictors of relapse and death
Variables DFS OS
HR 95% CI P value HR 95% CI P value
pre-ER NS 0.271 0.119-0.619 0.002
pre-Ki-67 2.239 1.191-4.207 0.012 2.668 1.192-5.974 0.017
pos-Ki-67 2.174 1.019-4.637 0.045 4.646 1.918-11.258 0.001
pRT 3.588 1.104-11.660 0.034 9.796 1.304-73.567 0.027
pRT, pathological response in tumor site;95%CI, 95% confidence interval; HR, hazard ratio; NS, no significance.BMC Cancer 2009, 9:375 http://www.biomedcentral.com/1471-2407/9/375
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univariate analysis. However, the prognostic value of ER
status no longer existed after chemotherapy or when eval-
uated with multivariate analysis. A possible explanations
for the weakened prognostic power of ER is that the ER
status may change during the course of NC; this has been
confirmed by many other researchers [7,33,34], suggest-
ing the pre-treatment ER status might be more reliable for
predicting long-term outcome. Moreover, the association
of ER/PR status with other established indicators of favo-
rable prognosis such as pCR (more ER negative patients
than positive in pCR), and the use of adjuvant endocrine
therapies may have decreased the power of the multivari-
ate analysis.
Over-expression of HER-2 is associated with poor out-
comes in operable breast cancer. We failed to find any
relationship between pre- or post- HER-2 status and sur-
vival by univariate and multivariate analysis. This might
be explained by the poor outcome of LABC and limited
impact of HER-2 in this special group. We also found that
the lower pre- and post-Ki-67 expression (Ki-67 ≤ 20%)
were significantly correlated with better DFS and OS by
multivariate analysis. This finding supports the hypothe-
sis that rapidly growing tumors tend to have a poor prog-
nosis but are also more sensitive to chemotherapy,
especially to DNA structure-damaging agents like anthra-
cyclines. Honkoop et al. [35,36] and some other studies
[37-41] have demonstrated the prognostic value of the Ki-
67 index.
When evaluating the toxicity of therapy, the NE regimen
in this study was considered to be well tolerated. There
was no septicemia, serious cardiovascular toxicity or side
effect-related death. Neutropenia was the major hemato-
logic toxicity. Grade 3-4 neutropenia presented in 46.2%
patients enrolled but only 4.2% required hospitalization.
Affected patients recovered form neutropenia through
support of G-CSF and subsequent therapy was not influ-
enced by the previous neutropenia. Other hematologic
toxicities including anemia and thrombocytopenia were
infrequent. The most common nonhematologic toxicities
included alopecia, nausea/vomiting and mucositis.
Patients could tolerate the nonhematologic toxicities and
the therapeutic process was not greatly impacted.
Conclusion
In our experience with a median follow-up of 63.4
months, NC with vinorelbine and epirubicin intravenous
combination regimen is a promising treatment for nonin-
flammatory locally advanced breast cancer. In this study,
pathological response in tumors, high pre-Ki-67 and post-
Ki-67 expression, and pre-ER expression were the impor-
tant variables that predicted long-term outcome. Patients
with pathological special involvement in the primary site
Cumulative Disease-Free Survival Figure 1
Cumulative Disease-Free Survival. Kaplan-Meier sur-
vival estimates according to pathological response in tumor 
site Abbreviations: T-A, no tumor cell or presence of in situ 
carcinoma, no invasive tumor; T-B, presence of invasive car-
cinoma without special involvement (such as skin, vessel, 
more than one quadrant); T-C, presence of invasive carci-
noma with special involvement; Sig, significance. *Table 
within the figure was the log-rank P value between two 
curves.
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Sig. Sig. Sig.
T-A .000 .014
T-B .000 .000
T-C .014 .000
Cumulative Overall Survival Figure 2
Cumulative Overall Survival. Kaplan-Meier survival esti-
mates according to pathological response in tumor site 
Abbreviations: T-A, no tumor cell or presence of in situ car-
cinoma, no invasive tumor; T-B, presence of invasive carci-
noma without special involvement (such as skin, vessel, more 
than one quadrant); T-C, presence of invasive carcinoma 
with special involvement; Sig, significance. *Table within the 
figure was the log-rank P value between two curves.
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T-A .000 .027
T-B .000 .001
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after NC showed the worst survival rate, and therefore
deserve special attention in the future.
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